Northwest Biotherapeutics, Inc  

(Public, NASDAQ:NWBO)   Watch this stock  
0.00 (0.00%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.91 - 9.45
52 week 3.79 - 9.45
Open 9.12
Vol / Avg. 1.03M/726,578.00
Mkt cap 559.59M
P/E     -
Div/yield     -
EPS -2.32
Shares 70.31M
Beta 2.90
Inst. own 30%
Feb 9, 2015
Northwest Biotherapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -4895.07% -9328.34%
Operating margin -2864.11% -6925.31%
EBITD margin - -6955.43%
Return on average assets -389.84% -351.27%
Return on average equity - -
Employees 12 -
CDP Score - -


Suite 800, 4800 Montgomery Lane
United States - Map
+1-240-4979024 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Northwest Biotherapeutics, Inc., is a development stage biotechnology company focused on developing immunotherapy products to treat cancers, without toxicities of the kind associated with chemotherapies, and, through a proprietary batch manufacturing process, on a cost-effective affordable basis initially in both the United States and Europe. The Company is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than existing treatments, and without the side effects of chemotherapy drugs. The Company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The DCVax technology is expected to be applicable to most cancers, and is embodied in several distinct product lines: DCVax-L, DCVax-Direct and DCVax-Prostate.

Officers and directors

Linda F. Powers Chairperson of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Leslie J. Goldman Senior Vice President - Business Development
Age: 69
Bio & Compensation  - Reuters
Anthony E. Maida Ph.D. Senior Vice President - Clinical Research
Age: 61
Bio & Compensation  - Reuters
Marnix L. Bosch Ph.D Chief Technical Officer
Age: 54
Bio & Compensation  - Reuters
Alton L. Boynton Ph.D. Chief Scientific Officer, Director
Age: 70
Bio & Compensation  - Reuters
Robert A. Farmer Independent Director
Age: 74
Bio & Compensation  - Reuters
Jerry J. Jasinowski Independent Director
Age: 71
Bio & Compensation  - Reuters
Navid Malik Independent Director
Age: 45
Bio & Compensation  - Reuters